Replies to post #180262 on Kraig Biocraft Laboratories Inc (KBLB)

[DimesForShares]

Precisely why we can’t uplist.

Thank you Hope for sharing the regulations that show why KBLB is nowhere close to uplisting. As your post made it clear, all three paths require at least $4 million in equity. Currently KBLB has negative equity of perhaps $4 to $5 million, meaning the company will need at least $8 million to get us to where we need to be.

This equity cannot come from a loan of any kind, as loans decrease equity (since the loan must be repaid with interest).

Thompson perhaps has a potential exclusive licensing agreement that might provide a boost to our equity, but with projected sales of $2.4 million in 2020, it seems unlikely that a company would invest more than a million or so to be able to buy all $2.4 million of our product next year. That would be bad business indeed.

[es1]

That is a little confusing with the 1s vs 3s
But I believe you are saying
The nasdaq capital markets using the equity standard and closing price alternative.

If that is correct Kim needs a gift.

qualify under the closing price alternative, a company must have: (i) average annual revenues of $6 million for three years, or (ii) net tangible assets of $5 million, or (iii) net tangible assets of $2 million and a 3 year operating history, in addition to satisfying the other financial and liquidity requirements listed above.

Our current TOTAL assets are $800,000


What Are Net Tangible Assets?

Net tangible assets are calculated as the total assets of a company, minus any intangible assets such as goodwill, patents, and trademarks, less all liabilities and the par value of preferred stock. In other words, its focus is on physical assets such as property, plant, and equipment, as well as inventories and cash instruments.


Am I missing something?